| Title |
Development of a potent invigorator of immune responses endowed with both preventive and therapeutic properties
|
|---|---|
| Published in |
Biologics: Targets & Therapy, May 2017
|
| DOI | 10.2147/btt.s128308 |
| Pubmed ID | |
| Authors |
Gursaran P Talwar, Jagdish C Gupta, Abu S Mustafa, Hemanta K Kar, Kiran Katoch, Shreemanta K Parida, Prabhakara P Reddi, Niyaz Ahmed, Vikram Saini, Somesh Gupta |
| Abstract |
This article reviews briefly the making of an immunoprophylactic-cum-immunotherapeutic vaccine against leprosy. The vaccine is based on cultivable, heat-killed atypical mycobacteria, whose gene sequence is now known. It has been named Mycobacterium indicus pranii. It has received the approval of the Drug Controller General of India and the US Food and Drug Administration. Besides leprosy, M. indicus pranii has found utility in the treatment of category II ("difficult to treat") tuberculosis. It also heals ugly anogenital warts. It has preventive and therapeutic action against SP2/O myelomas. It is proving to be a potent adjuvant for enhancing antibody titers of a recombinant vaccine against human chorionic gonadotropin, with the potential of preventing pregnancy without derangement of ovulation and menstrual regularity in sexually active women. |
X Demographics
The data shown below were collected from the profiles of 3 X users who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Netherlands | 1 | 33% |
| United States | 1 | 33% |
| United Kingdom | 1 | 33% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 2 | 67% |
| Scientists | 1 | 33% |
Mendeley readers
The data shown below were compiled from readership statistics for 36 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 36 | 100% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Researcher | 6 | 17% |
| Student > Postgraduate | 4 | 11% |
| Student > Ph. D. Student | 3 | 8% |
| Other | 2 | 6% |
| Student > Master | 2 | 6% |
| Other | 4 | 11% |
| Unknown | 15 | 42% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 10 | 28% |
| Immunology and Microbiology | 4 | 11% |
| Agricultural and Biological Sciences | 2 | 6% |
| Unspecified | 1 | 3% |
| Pharmacology, Toxicology and Pharmaceutical Science | 1 | 3% |
| Other | 3 | 8% |
| Unknown | 15 | 42% |
Attention Score in Context
This research output has an Altmetric Attention Score of 2. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 29 May 2017.
All research outputs
#16,051,091
of 25,382,440 outputs
Outputs from Biologics: Targets & Therapy
#176
of 284 outputs
Outputs of similar age
#184,560
of 324,557 outputs
Outputs of similar age from Biologics: Targets & Therapy
#3
of 5 outputs
Altmetric has tracked 25,382,440 research outputs across all sources so far. This one is in the 34th percentile – i.e., 34% of other outputs scored the same or lower than it.
So far Altmetric has tracked 284 research outputs from this source. They typically receive a little more attention than average, with a mean Attention Score of 6.2. This one is in the 34th percentile – i.e., 34% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 324,557 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 40th percentile – i.e., 40% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 5 others from the same source and published within six weeks on either side of this one. This one has scored higher than 2 of them.